Compounds for Positron Emission Tomography
Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.
1 - 19 . (canceled)
20 . A conjugate of the formula
B-L-P
or a pharmaceutically acceptable salt thereof, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands, PSMA binding ligands, and PSMA inhibitors, L is a divalent linker, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a precursor thereof, or a radical of a compound capable of binding a radionuclide or radionuclide containing group, such as a metal chelating group.
21 . The conjugate of claim 20 comprising folate-Asp,
22 . The conjugate of claim 20 comprising folate-Arg.
23 . The conjugate of claim 20 wherein the linker comprises a polypeptide comprising lysine, arginine, or aspartic acid, or a combination thereof.
24 . The conjugate of claim 20 wherein the linker does not include a diradical of the formula NH—(CH 2 ) 2 —NH,
25 . The conjugate of claim 20 comprising the formula
or a derivative thereof comprising a chelated metal.
26 . The conjugate of claim 20 comprising folate-PEG.
27 . The conjugate of claim 26 comprising the formula
or a derivative thereof comprising a chelated metal.
28 . The conjugate of claim 26 comprising the formula
or a derivative thereof comprising a chelated metal.
29 . The conjugate of claim 20 wherein the targeting agent is a radical of a PSMA binding ligand or PSMA inhibitor.
30 . The conjugate of claim 29 comprising the formula
where n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or
where n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or
where W is O or S.
31 . The conjugate of claim 29 wherein the linker comprises a polypeptide comprising phenylalanine, lysine, arginine, or aspartic acid, or a combination thereof.
32 . The conjugate of claim 29 comprising the formula
or a derivative thereof comprising a chelated metal.
33 . The conjugate of claim 29 comprising the formula
where n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
34 . The conjugate of claim 29 wherein the linker comprises the formula
35 . The conjugate of claim 29 wherein the linker comprises the formula
36 . The conjugate of claim 33 comprising the formula
or a derivative thereof comprising a chelated metal.
37 . The conjugate of claim 20 , wherein the radionuclide is a positron-emitting radionuclide.
38 . The conjugate of claim 37 , wherein the positron-emitting radionuclide is selected from the group consisting of 89 Zr, 45 Ti, 51 Mn, 64 Cu, 61 Cu, 63 Zn, 82 Rb, 68 Ga, 66 Ga, 11 C, 13 N, 15 O, 124 I, 34 Cl, 18 F, and 19 F.
39 . The conjugate of claim 20 wherein the radionuclide is a radiotherapy agent.